Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
Status:
Completed
Trial end date:
2017-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if tivantinib (ARQ 197) is effective in treating
patients with MET diagnostic-high hepatocellular carcinoma (liver cancer) who have already
been treated once with another therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Daiichi Sankyo Inc. Daiichi Sankyo, Inc.
Collaborators:
ArQule ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.) Covance